Daily use of 600 mg magnesium shows the occurrence of migraine attacks to be reduced.
Magnesium may well affect the fase constriction and the release and activity of serotonin.
This is the result of a well designed (double-blind, placebo-controlled, randomized) study by Dr. A. Peikert the Department of Neurology and Clinical Neuropsychology at the Munich-health care
Seventy people have more than two years with migraine were members after a preparatory period of four weeks either a daily 600 mg magnesium (trimagnesiumdicitraat) or a placebo. After twelve weeks showed the number of migraine attacks in the group who received magnesium had steadily decreased to a total of 41.6%. In the placebo group, the reduction in the number of attacks, only 15.8%. The total number of days with migraine was in the magnesium group decreased by 49%, against 21% in the group who had received a placebo. But some complained (18.6%) of patients who had received magnesium on diarrhea, and 4.7% for stomach complaints.
The attacks in the magnesium group were lighter and less drug use.
Earlier studies have already indicated that migraine patients less magnesium in their bodies than others.